Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
I'rom Group
Tokyo, Japaniromgroup.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
I'rom Group operates commercial SMO and CRO services in Japan and Australia and develops advanced medicinal products using its Sendai virus vector and iPS cell technologies, with several in‑house gene and cell therapy programs and vaccines; it also supports late-stage and post‑approval trials for partners such as Evive Biotech.[1][3][5]
- Therapeutic areas
- OncologyCardiovascularOtherInfectious Diseases
- Modalities
- Gene therapyCell therapyVaccineBiologicRecombinant proteinSmall molecule
- Industry
- Biotech
02
Partnerships
Evive Biotech (development of efbemalenograstim alfa, Ryzneuta, in Japan)[3]Kyowa Pharmaceutical Industry (strategic clinical trial support alliance, historical)[4]Pharmaceutical companies and research institutes using Sendai virus vector and iPS cell tools (various, not individually disclosed)[1][5]
Beyond the preview
Go deeper on I'rom Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I'rom Group.